EGFR-mutated Lung Cancer in Randomized Investigator-Initiated Study

NCT06486142 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

200

Enrollment

OTHER

Sponsor class

Conditions

Non-Small Cell Lung Cancer

Interventions

DRUG: Afatinib/Dacomitinib
DRUG: Osimertinib

Sponsor

Region Skane

Collaborators

[object Object]